E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10012685 |
E.1.2 | Term | Diabetic polyneuropathy |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate efficacy and safety of Actovegin® (Actovegin) versus placebo given as intravenous (i.v.) infusions once daily for 20 days, followed by oral treatment for 140 days in patients with symptomatic diabetic peripheral polyneuropathy. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Has the patient given informed consent according to local requirements before any trial related activities? A trial related activity is any procedure that would not have been performed during the routine management of the patient. 2. Is the patient aged ≥ 18 to ≤ 65 years? 3. Does the patient suffer from type 2 diabetes mellitus? 4. Has the patient evidence of symptomatic diabetic peripheral polyneuropathy, i.e. TSS ≥6 and NIS-LL ≥ 2? 5. Is the patient’s VPT measured to ≤ 30V? 6. Has the patient adequate circulation to the foot as evidenced by a palpable pulse on posterior tibialis artery and dorsal artery of foot? 7. Is the HbA1C level less than 10%? 8. Is the patient able to make frequent clinic visits over the trial period?
For patients receiving tricyclic antidepressants, anticonvulsants, mexiletine or neuroleptics as treatment of neuropathic pain: 9. Has the regimen been stable within the last month?
For female patients of childbearing potential (childbearing potential is considered until menopause has lasted more than 12 months): 10. Does the patient use an acceptable contraceptive method (hormonal pills, patches, implants, injections or intrauterine device)? 11. Is the pregnancy test negative before the 1st dose of IMP? (Surgically hysterectomised and surgically successfully sterilized females may be included on the same conditions as male patients). |
|
E.4 | Principal exclusion criteria |
1. Does the patient suffer from known allergy towards Actovegin or similar preparations? 2. Has the patient asymmetrical neuropathy of the trunk or proximal lower limbs? 3. Does the patient suffer from diabetic foot ulceration or infections? 4. Does the patient suffer from diabetic amyotrophy? 5. Does the patient suffer from decompensated cardiac insufficiency, pulmonary oedema, oliguria, anuria, generalised oedema? 6. Does the patient suffer from polyneuropathy due to other underlying causes? 7. Has the patient been hospitalised due to diabetic polyneuropathy within the last month? 8. Has the patient participated in any other trial with an Investigational Medicinal Product (IMP) or device within 30 days before inclusion in this trial? 9. Has the patient ever used medications that may be etiological factors for neuropathy, such as isoniazid, nitrofurantoin, vincristine and phenytoin? 10. Has the patient used cerebrolysin or α-lipoic acid or received Transcutaneous Electric Nerve Stimulation (TENS) or acupuncture within the last month? 11. Has the patient received opiates as treatment of his / her diabetic polyneuropathy within the last month? 12. Does the patient suffer from any malignancy? 13. Is the patient nursing? 14. Does the patient suffer from any mental, psychiatric or other conditions that may compromise data collection and understanding of written and verbal information given in the trial? 15. Does the patient suffer from present and / or previous chronic alcohol abuse? 16. Is there any anamnestic evidence of hypothyroidism? 17. Is there any anamnestic evidence of vitamin B12 deficiency? 18. Does the patient suffer from an impaired renal function with high blood urea nitrogen (BUN) and / or increased serum creatinine (>120 μmol/L)?
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Average of TSS over the treatment period calculated by Area Under the Curve (AUC), divided by the treatment period in number of days. According to recommendations (30), positive neuropathic sensory symptoms can serve as important endpoints for controlled clinical trials in diabetic polyneuropathy, since they are symptoms of which patients complain and for which patients come to doctors seeking relief. In tertiary neuromuscular practice, painful neuropathy is among the most common reasons for referral. The TSS range from 0 (no symptoms) to 14.64 points (all symptoms and [almost] continuously present between the groups receiving Actovegin and placebo (31).
Average of the VPT over the treatment period using the same methods as for the TSS using Bio-Thesiometer, which is a quantitative sensory testing device. According to the guidelines for clinical investigations for medicinal products in the treatment of diabetes mellitus (32), efficacy should be based on clinical symptoms and signs, however, quantitative sensory tests, e.g. for vibration, can be supportive. There are published data, suggesting that test of VPT can be used as a clinical predictor for foot ulceration in diabetic patients with established neuropathy (33), and it is anticipated that vibratory sensations are conveyed by large diameter fibers, while neuropatic pain primarily conveyed by small-fiber sensations (34). There are data indicating that VPT examinations obtained with a simple, relatively inexpensive device, such as Bio- Thesiometer, are comparable to those obtained using more elaborate equipment and testing methods (35). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 1 |